{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:14:17Z","timestamp":1789726457257,"version":"4.0.1"},"reference-count":31,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2012,8,22]],"date-time":"2012-08-22T00:00:00Z","timestamp":1345593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Parkinson's disease dementia (PDD) is associated with cholinergic deficits. This report presents an efficacy and safety study of the acetylcholinesterase inhibitor donepezil hydrochloride in PDD. PDD patients (n = 550) were randomized to donepezil (5 or 10 mg) or placebo for 24 weeks. Coprimary end points were the Alzheimer's Disease Assessment Scale\u2013cognitive subscale (ADAS\u2010cog) and Clinician's Interview\u2010Based Impression of Change plus caregiver input (CIBIC+; global function). Secondary end points measured executive function, attention, activities of daily living (ADLs), and behavioral symptoms. Safety and tolerability were assessed. ADAS\u2010cog mean changes from baseline to week 24 (end point) were not significant for donepezil in the intent\u2010to\u2010treat population by the predefined statistical model (difference from placebo: \u22121.45,\n                    <jats:italic>P<\/jats:italic>\n                    = .050, for 5 mg; \u22121.45,\n                    <jats:italic>P<\/jats:italic>\n                    = .076, for 10 mg). Alternative ADAS\u2010cog analysis, removing the treatment\u2010by\u2010country interaction term from the model, revealed significant, dose\u2010dependent benefit with donepezil (difference from placebo: \u22122.08,\n                    <jats:italic>P<\/jats:italic>\n                    = .002, for 5 mg; \u22123.31,\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .001, for 10 mg). The 10\u2010mg group, but not the 5\u2010mg group, had significantly better CIBIC+ scores compared with placebo (3.7 vs 3.9,\n                    <jats:italic>P<\/jats:italic>\n                    = .113, for 5 mg; 3.6 vs 3.9,\n                    <jats:italic>P<\/jats:italic>\n                    = .040, for 10 mg). Secondary end points\u2014Mini\u2013Mental State Exam; Delis\u2013Kaplan Executive Function System; Brief Test of Attention, representing cognitive functions particularly relevant to PDD\u2014showed significant benefit for both donepezil doses (\n                    <jats:italic>P<\/jats:italic>\n                    \u2264 .007). There were no significant differences in ADLs or behavior. Adverse events were more common with donepezil but mostly mild\/moderate in severity. Although the study did not achieve its predefined primary end points, it presents evidence suggesting that donepezil can improve cognition, executive function, and global status in PDD. Tolerability was consistent with the known safety profile of donepezil. \u00a9 2012 Movement Disorder Society\n                  <\/jats:p>","DOI":"10.1002\/mds.25098","type":"journal-article","created":{"date-parts":[[2012,8,22]],"date-time":"2012-08-22T10:37:11Z","timestamp":1345631831000},"page":"1230-1238","source":"Crossref","is-referenced-by-count":176,"title":["Donepezil in Parkinson's disease dementia: A randomized, double\u2010blind efficacy and safety study"],"prefix":"10.1002","volume":"27","author":[{"given":"Bruno","family":"Dubois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Tolosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Katzenschlager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Emre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Lees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Pourcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jina","family":"Swartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"Moline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,8,22]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.14.2.223"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000306632.43729.24"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm111"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004019900168"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq059"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410290616"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(83)90096-3"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ab2b58"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d55f61"},{"key":"e_1_2_5_11_2","first-page":"184","article-title":"Dementia and Parkinson's disease: biochemical and anatomo\u2010clinical correlation","volume":"141","author":"Dubois B","year":"1985","journal-title":"Rev Neurol (Paris)"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1204"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.949"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-211-33328-0_3"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041470"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.050682"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.3.181"},{"issue":"3","key":"e_1_2_5_18_2","first-page":"S11","article-title":"Parkinsonism: onset, progression, and mortality. 1967","volume":"57","author":"Hoehn MM","year":"2001","journal-title":"Neurology"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.5.1113"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.141.11.1356"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610296002645"},{"key":"e_1_2_5_23_2","volume-title":"Brief Test of Attention\u2122: Professional Manual","author":"Schretlin D","year":"1997"},{"key":"e_1_2_5_24_2","volume-title":"D\u2010KEFS\u2122 Technical and Examiner's Manual","author":"Delis DC","year":"2001"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.5014\/ajot.53.5.471"},{"key":"e_1_2_5_26_2","first-page":"152","volume-title":"Third Symposium on Parkinson's Disease","author":"Schwab RS","year":"1969"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.12.2308"},{"key":"e_1_2_5_28_2","first-page":"153","volume-title":"Recent Developments in Parkinson's Disease","author":"Fahn S","year":"1987"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199700112-00004"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1133"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280202"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10566"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.25098","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.25098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:29:43Z","timestamp":1760959783000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.25098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,22]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1002\/mds.25098"],"URL":"https:\/\/doi.org\/10.1002\/mds.25098","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,22]]}}}